%0 Journal Article
%T Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function
%J -
%D 2019
%R https://doi.org/10.1038/s41409-019-0524-2
%X We retrospectively reviewed the impact of impaired renal function (eGFR <£¿45£¿ml/min/SA) on post-transplant outcomes in patients receiving ASCT for AL amyloidosis. Patients were grouped into two cohorts, those with normal renal function (NRF) eGFR ¡Ý£¿45£¿ml/min (n£¿=£¿568) and those with impaired renal function (IRF) eGFR <£¿45£¿ml/min (n£¿=£¿87). Patients with IRF had higher renal stage (>Stage 1: 100% IRF vs 37% NRF, p£¿<£¿0.0001) and the majority received conditioning with melphalan <200£¿mg/m2 (70% IRF vs 21% NRF, p£¿<£¿0.0001). Forty-four patients (6.7%) required dialysis within 100 days of ASCT. Renal stage predicted for dialysis institution within 100 days of ASCT (3% Stage I vs 10% Stage II vs 22% Stage III, p£¿<£¿0.0001). Dialysis within 100 days was higher in the IRF cohort (16% for IRF cohort vs 6% for NRF cohort, p£¿=£¿0.0007. Patients with impaired renal function were more likely to be admitted to hospital (80% IRF vs 70% NRF, p£¿=£¿0.03). The 100-day mortality was higher in the IRF cohort (14% IRF cohort vs 5% NRF cohort, p£¿=£¿0.008). Median OS and PFS were similar between the two cohorts. Impaired renal function predicts for a higher rate of hospitalization, progression to dialysis and early mortality in patients receiving ASCT for AL amyloidosis
%U https://www.nature.com/articles/s41409-019-0524-2